Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease

D.H.F. Gommans, J. Nas, S.J. Pinto-Sietsma, Y. Koop, R.E. Konst, F. Mensink, G.W.A. Aarts, L.S.F. Konijnenberg, K. Cortenbach, D.V.M. Verhaert, J. Thannhauser, J.Q. Mol, M.J.P. Rooijakkers, J.L. Vos, A. van Rumund, P. Vart, R.J. Hassing, J.H. Cornel, C.P.C. de Jager, M.M. van den HeuvelH.G. van der Hoeven, A. Verbon, Y.M. Pinto, N. van Royen, R.R.J. van Kimmenade, P.W. de Leeuw, M.A. van Agtmael, P. Bresser, W.H. van Gilst, A. Vonk-Noordergraaf, J.G.P. Tijssen, C.o.m.m. Event, S.a.f.e.t.y. Data, C.o.m.m. Steering, Data Safety Monitoring Board, Event Committee, Steering Comm

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)60-68
Number of pages9
JournalAmerican Heart Journal
Volume226
DOIs
Publication statusPublished - 1 Aug 2020

Keywords

  • ace2
  • angiotensin-converting enzyme-2
  • coronavirus
  • receptor
  • sars
  • ANGIOTENSIN-CONVERTING ENZYME-2
  • ACE2
  • RECEPTOR
  • SARS
  • CORONAVIRUS

Cite this